KR987000085A - 헤지호그-유래의 신규한 폴리펩티드(Novel Hedgehog-Derived Polypeptides) - Google Patents

헤지호그-유래의 신규한 폴리펩티드(Novel Hedgehog-Derived Polypeptides) Download PDF

Info

Publication number
KR987000085A
KR987000085A KR1019970703752A KR19970703752A KR987000085A KR 987000085 A KR987000085 A KR 987000085A KR 1019970703752 A KR1019970703752 A KR 1019970703752A KR 19970703752 A KR19970703752 A KR 19970703752A KR 987000085 A KR987000085 A KR 987000085A
Authority
KR
South Korea
Prior art keywords
polypeptide
antibody
amino acid
hedgehog
acid sequence
Prior art date
Application number
KR1019970703752A
Other languages
English (en)
Other versions
KR100453096B1 (ko
Inventor
에이. 비치 필립
티. 문 랜달
Original Assignee
하워드 더블유. 칼리파노
더 존스 홉킨스 유니버시티 스쿨 오브 메디신
카렌 엘. 데이얼
유니버시티 오브 워싱턴
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 하워드 더블유. 칼리파노, 더 존스 홉킨스 유니버시티 스쿨 오브 메디신, 카렌 엘. 데이얼, 유니버시티 오브 워싱턴 filed Critical 하워드 더블유. 칼리파노
Publication of KR987000085A publication Critical patent/KR987000085A/ko
Application granted granted Critical
Publication of KR100453096B1 publication Critical patent/KR100453096B1/ko

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/033—Rearing or breeding invertebrates; New breeds of invertebrates
    • A01K67/0333—Genetically modified invertebrates, e.g. transgenic, polyploid
    • A01K67/0337—Genetically modified Arthropods
    • A01K67/0339—Genetically modified insects, e.g. Drosophila melanogaster, medfly
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43577—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
    • C07K14/43581—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies from Drosophila
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/40—Fish
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/50—Amphibians, e.g. Xenopus
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/70—Invertebrates
    • A01K2227/706—Insects, e.g. Drosophila melanogaster, medfly
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Insects & Arthropods (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Plant Pathology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Endocrinology (AREA)

Abstract

본 발명은 각각 헤지호그의 N 및 C 단편 또는 N-말단 및 C-말단 단편이라 칭하는 신규한 두 개의 폴리펩티드를 제공하는 것에 관한 것이다. 상기 두 개의 신규한 폴리펩티드는 천연 단백질내의 자가 단백질 분해 영역에 의해 인식되는 G↓CF 위치에서의 특이성 분해후에 유도된다. 또한, 본 발명은 상기 N 및 C 단편의 사용방법을 제공한다.

Description

헤지호그-유래의 신규한 폴리펩티드(Novel Hedgehog-Derived Polypeptides)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (31)

  1. 헤지호그 단백질의 아미노 말단 아미노산으로부터 유래한 아미노산 서열을 보유하고, 카르복시 말단에 천연 헤지호그 폴리펩티드의 카르복시 말단 단편의 단백질 분해 활성에 의해 특이적으로 인식되는 G↓CF 절단 위치를 보유하는 것을 특징으로 하는 거의 순수한 폴리펩티드.
  2. 제 1 항의 아미노산 서열을 보유하는 폴리펩티드를 암호화하는 분리된 폴리뉴클레오티드 서열.
  3. 제 2 항에 있어서, 제 1 항의 폴리펩티드의 아미노산 서열을 보유하는 폴리펩티드를 암호화하고, 제 1 항의 폴리펩디드와 면역반응하는 항체에 대한 하나 이상의 에피토프를 보유하는 분리된 폴리뉴클레오티드 서열.
  4. 제 2 항의 폴리뉴클레오티드를 함유하는 재조합 발현 벡터.
  5. 제 4 항의 발현 백터를 함유하는 숙주 세포.
  6. 제 1 항의 폴리펩티드에 결합하고, 제 1 항의 폴리펩티드의 면역반응성 단편에 결합하는 항체.
  7. 제 6 항에 있어서, 상기 항체가 다중클론 항체인 항체.
  8. 제 6 항에 있어서, 상기 항체가 단일클론 항체인 항체.
  9. 헤지호그 단백질의 카르복시 말단 아미노산으로부터 유래한 아미노산 서열을 보유하고, 아미노 말단에 천연 헤지호그 폴리펩티드의 카르복시 말단 단편의 단백질 분해 활성에 의해 특이적으로 인식되는 G↓CF 절단 위치를 보유하는 것을 특징으로 하는 거의 순수한 폴리펩티드.
  10. 제 9 항의 아미노산 서열을 보유하는 폴리펩티드를 암호화하는 분리된 폴리뉴클레오티드 서열.
  11. 제 10 항에 있어서, 제 9 항의 폴리펩티드의 아미노산 서열을 보유하는 폴리펩티드를 암호화하고, 제 9 항의 폴리펩디드와 면역반응하는 항체에 대한 하나 이상의 에피토프를 보유하는 분리된 폴리뉴클레오티드 서열.
  12. 제 10 항의 폴리뉴클레오티드를 함유하는 재조합 발현 벡터.
  13. 제 12 항의 발현 백터를 함유하는 숙주 세포.
  14. 제 9 항의 폴리펩티드에 결합하고, 제 9 항의 폴리펩티드의 면역반응성 단편에 결합하는 항체.
  15. 제 14 항에 있어서, 상기 항체가 다중클론 항체인 항체.
  16. 제 14 항에 있어서, 상기 항체가 단일클론 항체인 항체.
  17. 신경 세포와 헤지호그 폴리펩티드를 접촉시키는 단계를 포함하는, 신경 세포의 증식 또는 분화를 조절하는 방법.
  18. 제 17 항에 있어서, 상기 헤지호그 폴리펩티드가 제 1 항의 폴리펩티드인 방법.
  19. 제 17 항에 있어서, 상기 헤지호그 폴리펩티드가 제 9 항의 폴리펩티드인 방법.
  20. 제 17 항에 있어서, 상기 조절이 증식 또는 분화의 유도인 방법.
  21. 제 17 항에 있어서, 상기 신경 세포가 거의 바닥판 신경 세포로부터 유래하는 방법.
  22. 제 21 항에 있어서, 상기 신경 세포가 운동 신경인 방법.
  23. 제 17 항에 있어서, 상기 신경 세포가 척추동물 신경세포인 방법.
  24. 제 23 항에 있어서, 상기 척추동물이 인간인 방법.
  25. 제 17 항에 있어서, 상기 세포와 TGF-β류를 접촉시키는 단계를 추가로 포함하는 방법.
  26. 제 25 항에 있어서, 상기 TGF-β가 액티빈인 방법.
  27. 제 17 항에 있어서, 상기 세포와 신경 유도제를 접촉시키는 단계를 추가로 포함하는 방법.
  28. 제 27 항에 있어서, 상기 신경 유도제가 노긴, 폴리스타틴 및 뉴로트로핀으로 구성되는 군으로부터 선택되는 방법.
  29. 제 9 항의 폴리펩티드의 단백질 분해 영역을 포함하는 제 1 폴리펩티드, 상기 제 1 폴리펩티드에 의해 인식되는 절단 위치 및 제 2 폴리펩티드를 포함하는 자가 단백질 분해성 융합 단백질.
  30. 제 29 항의 융합 단백질을 암호화하는 폴리뉴클레오티드.
  31. 제 9 항의 폴리펩티드의 단백질 분해 영역 및 상기 단백질 분해 영역에 의해 인식되는 절단 위치를 포함하는 제 1 폴리펩티드를 암호화하는 제 1 폴리뉴클레오티드와 제 2 폴리펩티드를 암호화하는 제 2 폴리뉴클레오티드를 작동가능하게 연결시키는 단계를 포함하는, 자가 단백질 분해성 융합 단백질의 제조 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019970703752A 1994-12-02 1995-12-04 헤지호그-유래의신규한폴리펩티드 KR100453096B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/349498 1994-12-02
US8/349498 1994-12-02
US08/349,498 US6281332B1 (en) 1994-12-02 1994-12-02 Hedgehog-derived polypeptides
PCT/US1995/015923 WO1996016668A1 (en) 1994-12-02 1995-12-04 Novel hedgehog-derived polypeptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR10-2004-7006632A Division KR20040064700A (ko) 1994-12-02 1995-12-04 헤지호그-유래의 신규한 폴리펩티드

Publications (2)

Publication Number Publication Date
KR987000085A true KR987000085A (ko) 1998-03-30
KR100453096B1 KR100453096B1 (ko) 2005-04-06

Family

ID=23372653

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1019970703752A KR100453096B1 (ko) 1994-12-02 1995-12-04 헤지호그-유래의신규한폴리펩티드
KR10-2004-7006632A KR20040064700A (ko) 1994-12-02 1995-12-04 헤지호그-유래의 신규한 폴리펩티드

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR10-2004-7006632A KR20040064700A (ko) 1994-12-02 1995-12-04 헤지호그-유래의 신규한 폴리펩티드

Country Status (9)

Country Link
US (2) US6281332B1 (ko)
EP (1) EP0793502A4 (ko)
JP (2) JPH11500605A (ko)
KR (2) KR100453096B1 (ko)
AU (2) AU712346B2 (ko)
CA (1) CA2206509C (ko)
FI (1) FI121366B (ko)
NO (1) NO323079B1 (ko)
WO (2) WO1996017924A2 (ko)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6165747A (en) * 1993-12-30 2000-12-26 President & Fellows Of Harvard College Nucleic acids encoding hedgehog proteins
WO1995023223A1 (en) 1994-02-25 1995-08-31 The Trustees Of Columbia University In The City Of New York Dna encoding the vertebrate homolog of hedgehog, vhh-1, expressed by the notochord, and uses thereof
US6911528B1 (en) 1994-12-02 2005-06-28 The Johns Hopkins University School Of Medicine Hedgehog-derived polypeptides
DK0935656T3 (da) 1996-09-20 2006-12-11 Harvard College Hedgehog interagerende proteiner og anvendelser relateret dertil
WO1998030576A1 (en) * 1996-10-07 1998-07-16 The Johns Hopkins University School Of Medicine Novel hedgehog-derived polypeptides
DK1019490T3 (da) 1997-02-10 2010-03-15 Harvard College Fremgangsmåder til modulering af hæmatopoese og vaskulær vækst
AU8173098A (en) 1997-06-27 1999-01-19 Ontogeny, Inc. Neuroprotective methods and reagents
US7144997B2 (en) 1997-07-24 2006-12-05 Curis, Inc. Vertebrate embryonic patterning-inducing proteins, compositions and uses related therto
EP1009424A2 (en) * 1997-08-29 2000-06-21 Ontogeny, Inc. Regulation of muscle tissues by hedgehog-like polypeptides, and formulations and uses related thereto
US7361336B1 (en) 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
US6639051B2 (en) * 1997-10-20 2003-10-28 Curis, Inc. Regulation of epithelial tissue by hedgehog-like polypeptides, and formulations and uses related thereto
IL136230A0 (en) 1997-11-28 2001-05-20 Roche Diagnostics Gmbh An active hedgehog-protein-mutant, a process for its preparation and its use for pharmaceutical purposes
EP0919618A1 (de) * 1997-11-28 1999-06-02 Boehringer Mannheim Gmbh Aktive Hedgehog-Protein-Mutante, Verfahren zur Herstellung und Verwendung
DE69830192T2 (de) * 1997-12-03 2006-01-12 Biogen Idec Ma Inc., Cambridge Hydrophobisch-modifizierte Hedgehog Protein Zusammensetzungen und Verfahren
US6897297B1 (en) 1997-12-03 2005-05-24 Curis, Inc. Hydrophobically-modified protein compositions and methods
AU1902999A (en) * 1997-12-03 1999-06-16 Biogen, Inc. Hydrophobically-modified protein compositions and methods
US6004937A (en) * 1998-03-09 1999-12-21 Genetics Institute, Inc. Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11]
DK0953576T3 (da) * 1998-04-30 2006-03-20 Curis Inc Aktivt hedgehog-proteinkonjugat, fremgangsmåde til fremstilling heraf og anvendelse
JP2002524528A (ja) 1998-09-11 2002-08-06 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ ヘッジホッグ様ポリペプチドによる肺組織の調節、およびそれに関する製剤および使用方法
DE69942063D1 (de) * 1998-09-11 2010-04-08 Curis Inc Antagonisten von 'hedgehog' und 'patched' zur inhibierung des wachstums und der differenzierung von zellen und geweben, als auch deren verwendungen
US6159950A (en) * 1998-10-16 2000-12-12 Cornell Research Foundation, Inc. Method of modulating hair growth
US6884770B1 (en) 1998-11-06 2005-04-26 Curis, Inc. Methods and compositions for treating or preventing peripheral neuropathies
JP2003524388A (ja) * 1998-12-03 2003-08-19 バイオジェン インコーポレイテッド 興奮毒性を含む疾患を治療するための方法及び組成物
US8168178B2 (en) 1999-11-30 2012-05-01 Curis, Inc. Methods and compositions for regulating lymphocyte activity
US6951839B1 (en) 1999-11-30 2005-10-04 Curis, Inc. Methods and compositions for regulating lymphocyte activity
US7115653B2 (en) 2000-03-30 2006-10-03 Curis, Inc. Small organic molecule regulators of cell proliferation
US6613798B1 (en) 2000-03-30 2003-09-02 Curis, Inc. Small organic molecule regulators of cell proliferation
US6683192B2 (en) * 2000-03-30 2004-01-27 Curis, Inc. Small organic molecule regulators of cell proliferation
US8852937B2 (en) 2000-03-30 2014-10-07 Curis, Inc. Small organic molecule regulators of cell proliferation
US6683108B1 (en) 2000-03-30 2004-01-27 Curis, Inc. Agonists of hedgehog signaling pathways and uses related thereto
JP4954426B2 (ja) * 2000-06-16 2012-06-13 キュリス，インコーポレイテッド 血管形成調節組成物及び利用
US6942988B2 (en) * 2000-09-22 2005-09-13 The Johns Hopkins University School Of Medicine Method of use of sonic hedgehog protein as a ligand for patched
US20040060568A1 (en) 2000-10-13 2004-04-01 Henryk Dudek Hedgehog antagonists, methods and uses related thereto
US6908732B2 (en) 2000-10-13 2005-06-21 President & Fellows Of Harvard College Compounds and methods for regulating cell differentiation
US6902881B2 (en) 2000-10-13 2005-06-07 President And Fellows Of Harvard College Compounds and methods for regulating cell differentiation
US7708998B2 (en) 2000-10-13 2010-05-04 Curis, Inc. Methods of inhibiting unwanted cell proliferation using hedgehog antagonists
TWI267378B (en) 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
US20040091857A1 (en) * 2001-07-20 2004-05-13 Nallur Girish N. Gene expression profiling
US7160725B2 (en) * 2001-11-13 2007-01-09 Curis, Inc. Hedgehog signaling promotes the formation of three dimensional cartilage matrices
EP1496905B1 (en) 2002-04-22 2008-08-13 Johns Hopkins University School of Medicine Modulators of hedgehog signaling pathways, compositions and uses related thereto
CA2495825C (en) * 2002-08-19 2015-03-17 Merck Patent Gesellschaft Mit Beschraenkter Haftung Variants of the major allergen phl p 1 from timothy grass
US9487823B2 (en) 2002-12-20 2016-11-08 Qiagen Gmbh Nucleic acid amplification
WO2004087870A2 (en) * 2003-03-25 2004-10-14 The Johns Hopkins University Neuronal cell lineages and methods of production thereof
US8043834B2 (en) 2003-03-31 2011-10-25 Qiagen Gmbh Universal reagents for rolling circle amplification and methods of use
JP5189763B2 (ja) 2003-04-11 2013-04-24 エテックス コーポレーション 骨誘導性骨材料
US20040248103A1 (en) * 2003-06-04 2004-12-09 Feaver William John Proximity-mediated rolling circle amplification
PL1675608T3 (pl) 2003-09-12 2007-11-30 Wyeth Corp Stałe fosforanowo wapniowe pałeczki do wstrzyknięć dla dostarczania białek osteogennych
ES2707393T3 (es) 2004-03-26 2019-04-03 Curis Inc Moduladores de interferencia de ARN de señalización de hedgehog y usos de los mismos
EP2789342A1 (en) 2004-06-17 2014-10-15 Thrasos Innovation, Inc. TDF-related compounds and analogs thereof
JP5204486B2 (ja) 2004-08-27 2013-06-05 インフィニティ ファーマスーティカルズ、インク． シクロパミンアナログ及びその使用方法
US7473678B2 (en) 2004-10-14 2009-01-06 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods of use thereof
US7517870B2 (en) 2004-12-03 2009-04-14 Fondazione Telethon Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization
US7850960B2 (en) 2004-12-30 2010-12-14 University Of Washington Methods for regulation of stem cells
EP1863908B1 (de) 2005-04-01 2010-11-17 Qiagen GmbH Reverse transkription und amplifikation von rna bei simultaner degradierung von dna
EP2468881A3 (en) * 2005-07-21 2012-08-15 Abbott Laboratories Multiple gene expression including sorf contructs and methods with polyproteins, pro-proteins, and proteolysis
AU2006283040B2 (en) 2005-08-22 2011-08-25 The Johns Hopkins University Hedgehog pathway antagonists to treat disease
EP1762627A1 (de) 2005-09-09 2007-03-14 Qiagen GmbH Verfahren zur Aktivierung einer Nukleinsäure für eine Polymerase-Reaktion
HUE026634T2 (en) 2005-09-20 2016-07-28 Thrasos Innovation Inc TDF-related compounds and analogues thereof
EP1945202A2 (en) * 2005-11-11 2008-07-23 Licentia OY Mammalian hedgehog signaling inhiabitors
WO2007067514A2 (en) * 2005-12-05 2007-06-14 Boston Biomedical Research Institute Methods for identifying modulators of hedgehog autoprocessing
US8147860B2 (en) 2005-12-06 2012-04-03 Etex Corporation Porous calcium phosphate bone material
US7625759B2 (en) 2005-12-19 2009-12-01 Genentech, Inc. Method for using BOC/CDO to modulate hedgehog signaling
EP2311505B1 (en) 2006-02-09 2013-11-06 BioMimetic Therapeutics, LLC Compositions and methods for treating bone
EP2007428A2 (en) 2006-04-05 2008-12-31 Genentech, Inc. Method for using boc/cdo to modulate hedgehog signaling
US9161967B2 (en) 2006-06-30 2015-10-20 Biomimetic Therapeutics, Llc Compositions and methods for treating the vertebral column
AU2007269712B2 (en) 2006-06-30 2013-02-07 Biomimetic Therapeutics, Llc PDGF-biomatrix compositions and methods for treating rotator cuff injuries
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
JP2010520295A (ja) 2007-03-07 2010-06-10 インフィニティ・ディスカバリー・インコーポレイテッド へテロ環状シクロパミン類似体及びその使用方法
WO2008109829A1 (en) 2007-03-07 2008-09-12 Infinity Pharmaceuticals, Inc. Cyclopamine lactam analogs and methods of use thereof
US20090061002A1 (en) 2007-09-05 2009-03-05 Venbrocks Rudolf A Calcium phospate based delivery of growth and differentiation factors to compromised bone
CN101917853B (zh) 2007-12-27 2014-03-19 无限药品股份有限公司 立体选择性还原的方法
NZ602861A (en) 2008-09-09 2014-03-28 Biomimetic Therapeutics Llc Platelet-derived growth factor compositions and methods for the treatment of tendon and ligament injuries
JP6141015B2 (ja) 2009-08-05 2017-06-07 インフィニティ ファーマスーティカルズ、インク． シクロパミン類似体の酵素によるアミノ基転移
EP2473500A2 (en) 2009-09-01 2012-07-11 Pfizer Inc. Benzimidazole derivatives
AU2011217784B2 (en) 2010-02-22 2014-10-09 Biomimetic Therapeutics, Llc. Platelet-derived growth factor compositions and methods for the treatment of tendinopathies
US9394313B2 (en) 2010-09-14 2016-07-19 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
US9056865B2 (en) 2010-10-20 2015-06-16 Pfizer Inc. Pyridine-2-derivatives as smoothened receptor modulators
US10034945B2 (en) 2012-07-13 2018-07-31 Trustees Of Tufts College Silk powder compaction for production of constructs with high mechanical strength and stiffness
WO2016196928A1 (en) 2015-06-04 2016-12-08 PellePharm, Inc. Topical formulations for delivery of hedgehog inhibitor compounds and use thereof
JP7025021B2 (ja) 2015-10-26 2022-02-24 プレジデント アンド フェローズ オブ ハーバード カレッジ 還元多糖および酸化多糖ならびにそれらの使用の方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8611832D0 (en) * 1986-05-15 1986-06-25 Holland I B Polypeptide
US5789543A (en) * 1993-12-30 1998-08-04 President And Fellows Of Harvard College Vertebrate embryonic pattern-inducing proteins and uses related thereto
EP0741783B1 (en) 1993-12-30 2009-03-18 President And Fellows Of Harvard College Vertebrate embryonic pattern-inducing hedgehog-like proteins

Also Published As

Publication number Publication date
AU712346B2 (en) 1999-11-04
NO323079B1 (no) 2006-12-27
EP0793502A4 (en) 1999-10-13
NO972494L (no) 1997-07-30
FI121366B (fi) 2010-10-29
JP2006151989A (ja) 2006-06-15
NO972494D0 (no) 1997-05-30
US6132728A (en) 2000-10-17
CA2206509A1 (en) 1996-06-06
JPH11500605A (ja) 1999-01-19
KR20040064700A (ko) 2004-07-19
US6281332B1 (en) 2001-08-28
FI972312A0 (fi) 1997-05-30
KR100453096B1 (ko) 2005-04-06
WO1996016668A1 (en) 1996-06-06
FI972312A (fi) 1997-12-30
AU4418396A (en) 1996-06-19
EP0793502A1 (en) 1997-09-10
CA2206509C (en) 2011-05-03
WO1996017924A2 (en) 1996-06-13
AU4370596A (en) 1996-06-26
WO1996017924A3 (en) 1996-09-26

Similar Documents

Publication Publication Date Title
KR987000085A (ko) 헤지호그-유래의 신규한 폴리펩티드(Novel Hedgehog-Derived Polypeptides)
Brewer Jr et al. [10] Isolation and characterization of apolipoproteins AI, A-II, and A-IV
Kaiser et al. The amino acid sequence of a myotoxic phospholipase from the venom of Bothrops asper
Molday et al. The cGMP-gated channel of the rod photoreceptor cell characterization and orientation of the amino terminus.
Jacobs et al. Isolation and molecular characterization of a surface‐bound proteinase of Entamoeba histolytica
Schönherr et al. Decorin core protein fragment Leu155-Val260 interacts with TGF-β but does not compete for decorin binding to type I collagen
BULLEID et al. Type-III procollagen assembly in semi-intact cells: chain association, nucleation and triple-helix folding do not require formation of inter-chain disulphide bonds but triple-helix nucleation does require hydroxylation
Settleman et al. Relationship of multiple forms of chromogranin.
KR960704038A (ko) 세포 표면 수용체 Hek와 결합하는 사이토킨(Cytokines That Bind the Cell Surface Receptor Hek)
KR970702917A (ko) Lag-3의 가용성 폴리펩타이드 절편 및 생산 방법, 치료 조성물, 항-이디오타입 항체
NO975435L (no) Modifiserte/kimeriske proteiner samt anvendelse derav
TR199900624T2 (xx) Proteinlerin y�ksek seviyede ekspresyonu.
BR9407377A (pt) Toxina hibrida
KR970707153A (ko) 카텝신 02 프로테아제(cathepsin 02 protease)
ES2129487T3 (es) Peptidos sinteticos, anticuerpos dirigidos contra ellos y su utilizacion.
KR960701899A (ko) 인자 viii:c활성을 갖는 단백질 복합체 및 그의 제조
Davis et al. Basic fibroblast growth factor induces 3T3 fibroblasts to synthesize and secrete a cyclophilin-like protein and β2-microglobulin
BASTIAN et al. Intra-and interchain disulfide bridges of the human J chain in secretory immunoglobulin A
DE69331501D1 (de) Unterdrückung der Proliferation von T-Zellen mittels Peptidfragmenten des basischen Proteins aus Myelin
DE69231567D1 (de) Screeningverfahren von morphogenischen Proteinen
DE69735242D1 (de) N-terminal verlängerte proteine exprimiert in hefe
CY1111763T1 (el) ΑΝΤΙΣΩΜΑΤΑ ΕΝΑΝΤΙΟΝ ΤΗΣ ΠΡΩΤΕΪΝΗΣ p51
Kerjan et al. Mammalian prolyl-tRNA synthetase corresponds to the≈ 150 kDa subunit of the high-Mr aminoacyl-tRNA synthetase complex
Lee et al. Vinculin binding site mapped on talin with an anti-idiotypic antibody.
DE69634757D1 (de) Vektor zur expression von n-terminal verlängerten proteinen in hefezellen

Legal Events

Date Code Title Description
A201 Request for examination
AMND Amendment
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
A107 Divisional application of patent
AMND Amendment
J201 Request for trial against refusal decision
B90T Transfer of trial file for re-examination
B701 Decision to grant
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20120924

Year of fee payment: 9

FPAY Annual fee payment

Payment date: 20130926

Year of fee payment: 10

FPAY Annual fee payment

Payment date: 20140923

Year of fee payment: 11

FPAY Annual fee payment

Payment date: 20150923

Year of fee payment: 12

EXPY Expiration of term